noscript

News and Announcements

Frost & Sullivan Identifies Proteomics International Laboratories as World-Leader in Predictive Diagnostics for Diabetic Kidney Disease

  • Published March 27, 2017 12:00AM UTC
  • Publisher Wholesale Investor
  • Categories Company Updates

Proteomics International Laboratories Ltd (ASX:PIQ) (PILL)  is the leader in predictive diagnostics diabetic kidney disease according to a Frost & Sullivan independent report released this month.  PILL managing director Dr Richard Lipscombe will be showcasing PromarkerD at the China-Australia Biotech Investment forum in Shanghai today.

KEY TAKEAWAYS:

  • The respected research house goes on to highlight PILL’s novel test for diabetic kidney disease, called PromarkerD, nothing its “high adoption potential”.
  • This follows news that the PromarkerD technology has been validated by the peer-reviewed scientific journal EuPA Open Proteomics, the official journal of the European Proteomics Association (EuPA).
  • Kidney disease is one of the major complications of diabetes and affects approximately one-third of all adult diabetics. Keeping people alive on dialysis costs more than $100,000 per person per year.
  • Globally the diabetes epidemic cost health systems $673 billion dollars in 2015.

There is currently no available test for predicting the onset of diabetic kidney disease and Frost & Sullivan suggest PILL is one of only two companies worldwide developing such a test. Results have shown PromarkerD can correctly predict 95% of previously kidney disease-free diabetic patients who go on to develop chronic kidney disease.

Dr Lipscombe said early detection is key to saving lives and money. “PromarkerD means we can accurately predict if someone will get the disease in the next four years so they can take lifestyle and medication action immediately to cut their risks,” he said.

“If we can stem this health crisis tsunami by identifying and treating people before they are symptomatic we are saving lives, as well as billions of dollars in health costs.”

PILL is recognised as a global leader in the field of proteomics.

Publication details

‘Biomarkers Enabling Diabetes and Obesity Management’ published by Frost & Sullivan, March 2, 2017. The report is available via PILL’s website (www.proteomicsinternational.com)

Request Information

Capital Insights
The Index Approach in Early-Stage Venture Capital: Reconsidered

The venture capital (VC) landscape is marked by its dynamism and complexity, especially in early-stage investing. The traditional approach in VC, characterised by a selective and intensive vetting process, often contrasts with the concept of ‘index investing.’ This article revisits the indexing approach in early-stage VC, incorporating insights from recent studies and data, including a […]

Capital Insights
The Future Is Now: The Evolution of Dealflow with Wholesale Investor

If you’ve ever thought of investing or expanding your portfolio, there’s no better time than the present. In the fast-paced world of investment, things are changing at a breathtaking speed, and it’s crucial to stay ahead of the game. The Future of Deal Flow is Today Dealflow, the lifeblood of the investment world, is not […]

Join over 45,000+ sophisticated investors

Join Now